Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.31 |
| ▸ | CDK9 | P50750 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12511944 | 1.00 | TLR4 (0.32) | TLR4NPC1CASP3RAB9ASENP8 | |
| SCHEMBL18134232 | 1.00 | TLR4 (0.32) | TLR4NPC1CASP3RAB9ASENP8 | |
| SCHEMBL8967097 | 0.96 | NPC1 (0.33) | TLR4NPC1CASP3RAB9ASENP8 | |
| SCHEMBL26216792 | 0.95 | CCNT1 (0.31) | CCNT1CDK9 | |
| SCHEMBL20929804 | 0.93 | — | — | |
| SCHEMBL18134233 | 0.93 | TLR4 (0.31) | TLR4 | |
| SCHEMBL9979144 | 0.93 | TLR4 (0.31) | TLR4NPC1CASP3RAB9ASENP8 | |
| SCHEMBL2935758 | 0.92 | TLR4 (0.31) | TLR4 | |
| SCHEMBL7645309 | 0.92 | — | — | |
| SCHEMBL13178281 | 0.92 | TLR4 (0.31) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1903090-B1 | Cyclohexene derivative having alkenyl, liquid crystal composition and liquid crystal display device | JNC CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7510749-B2 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | CHISSO CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1903090-A2 | Cyclohexene derivative having alkenyl, liquid crystal composition and liquid crystal display device | Chisso Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-20080063814-A1 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | CHISSO CORPORATION | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080063814-A1 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | POU2F2, HCN2, POU2F1 | TLR4 3962/4885NPC1 981/4885CASP3 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.